High level of soluble human leukocyte antigen (HLA)-G at beginning of pregnancy as predictor of risk of malaria during infancy by d'Almeida, Tania C. et al.
1Scientific RepoRts |          (2019) 9:9160  | https://doi.org/10.1038/s41598-019-45688-w
www.nature.com/scientificreports
High level of soluble human 
leukocyte antigen (HLA)-G at 
beginning of pregnancy as predictor 
of risk of malaria during infancy
tania C. d’Almeida1,2, Ibrahim sadissou3,4,5, Mermoz sagbohan3,5, Jacqueline Milet2, 
euripide Avokpaho  3, Laure Gineau2, Audrey sabbagh2, Kabirou Moutairou5, 
eduardo A. Donadi4, Benoit Favier6,7, Cédric pennetier8,9, Thierry Baldet8,9, Nicolas Moiroux  8,9, 
edgardo Carosella6,7, Philippe Moreau6,7, Nathalie Rouas-Freiss6,7, Gilles Cottrell2,3, David Courtin2 
& André Garcia2,3
placental malaria has been associated with an immune tolerance phenomenon and a higher 
susceptibility to malaria infection during infancy. HLA-G is involved in fetal maternal immune tolerance 
by inhibiting maternal immunity. During infections HLA-G can be involved in immune escape of 
pathogens by creating a tolerogenic environment. Recent studies have shown an association between 
the risk of malaria and HLA-G at both genetic and protein levels. Moreover, women with placental 
malaria have a higher probability of giving birth to children exhibiting high sHLA-G, independently of 
their own level during pregnancy. Our aim was to explore the association between the level of maternal 
soluble HLA-G and the risk of malaria infection in their newborns. Here, 400 pregnant women and 
their children were actively followed-up during 24 months. The results show a significant association 
between the level of sHLA-G at the first antenatal visit and the time to first malaria infection during 
infancy adjusted to the risk of exposure to vector bites (aHR = 1.02, 95%CI [1.01–1.03], p = 0.014). The 
level of sHLA-G is a significant predictor of the occurrence of malaria infection during infancy consistent 
with the hypothesis that mother sHLA-G could be a biomarker of malaria susceptibility in children.
Children born to mother with placental malaria (PM) seem to have a shorter delay of occurrence of the first 
malaria infection1–4. This phenomenon is referred as immune tolerance (IT) that may be due to modifications of 
the newborn immune system development involving at least some cytokines production in cord blood5. These 
modifications may induce differential immune responses involving IL10 and Interferon-γ during infancy6. A 
similar phenomenon was described in cases of filariasis infection during pregnancy7,8. It has been shown that 
children born to mothers with PM were also at an increased risk for non-malarial fever9. Moreover, a recent result 
shows that children born to mothers with PM tend to have an increased risk for the first malaria attack but not for 
subsequent ones10. These observations highlight that it is a very complex phenomenon that could imply immunity 
to a broader sense, not specific to malaria infection and not only related to PM infection.
Human leucocyte antigen-G (HLA-G) is an immune-modulatory molecule that plays a crucial role in 
materno-foetal tolerance during pregnancy11,12 by interacting with immune cells of both innate and adaptive 
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responses13,14. HLA-G is a non-classical HLA class I antigen, which differs from classical class I molecules in its 
restricted tissue distribution, diversity of protein isoforms and limited polymorphism15,16. The soluble isoforms 
detected in the plasma are shed HLA-G1 (HLA-G1s) and HLA-G511. Apart from pregnancy, HLA-G has been 
described associated with chronic viral infections, cancer and in vitro fertilization success17–22. During viruses’ 
infections, HLA-G can be over-expressed by infected cells to create a tolerogenic environment helping the patho-
gen to escape immune system23. The same phenomenon has been described in several types of cancers24.
The association between HLA-G and the risk of malaria has been shown recently by our team at genetic25,26 
and protein levels27,28. These last studies have been performed in different populations and geographic areas 
(Senegal in 2003 and Benin in 2010–2011). It clearly appears that the level of sHLA-G in children during the 
first year of life is strongly correlated with their own risk of malaria infection during the weeks following the 
measurement28. The sHLA-G level of a child was also associated with the sHLA-G level of his mother not only at 
delivery28 but also during the overall pregnancy29. Moreover, mothers with PM have a higher probability of giving 
birth to a child with a high level of sHLA-G during the first 2 years of life, independently of the mothers’ sHLA-G 
level29. Altogether, these results are consistent with both the fact that the risk of malaria infection during infancy 
is associated with the levels of sHLA-G in children and with the potential involvement of HLA-G in the immune 
tolerance phenomenon described during PM.
However, the direct association between the mothers’ levels of soluble HLA-G and the risk of malaria for their 
newborns remained unexplored. Here, our aim was to study the association between the mothers’ sHLA-G levels 
throughout the pregnancy and the risk of malaria during her newborn’s first 24 months of life.
Results
Descriptive results. Women’s mean age was 25.9 years (95% confidence interval [25.4–26.5]) and 15.7% 
were primigravid (Table 1). During the follow-up 16% of the mothers were infected by P. falciparum at first 
ANV (antenatal visit) and 4.9% at the second. Only two women were infected twice. The prevalence of PM was 
10.8%. The mean level of soluble HLA-G at ANV1, ANV2 and at delivery are respectively 10.1 ng/ml (SD = 13.6), 
10.6 ng/ml (SD = 14.0) and 17.3 ng/ml (SD = 34.6). Using multivariate linear regression, the level of sHLA-G did 
not differ significantly according to placental infection (p = 0.07, n = 370) or to peripheral infection at ANV1 
(p = 0.67, n = 379), ANV2 (p = 0.71, n = 364) and at delivery (p = 0.26, n = 370).
In children, mean birth weight was 3034 g (95%CI, [2992.5–3075.4]), 9.0% of them had a LBW, and 14 (3.5%) 
were preterm.
Groups Covariates Characteristics
Mothers 
(n = 400)
Age (years) 25.9 SD = 5.4
Gravidity
  Primigravid 15.75%
  Multigravid 84.25%
Placental malaria 10.8%
Peripheral malaria
  ANV1(a) 16.0%
  ANV2 4.9%
  Delivery 15.9%
Ethnicity
  Aïzo 69.50%
  Fon 20.75%
  Others 9.75%
Married 97.8%
ITP group(b)
  SP 34.5%
  MQFD 35.5%
  MQSD 30.0%
Health center
  Sékou 76.0%
  Atogon 24.0%
Infants 
(n = 400)
Birth weight (grams) 3033.9 SD = 420.4
Low birth weight 9.0%
Gender
  Female 53.0%
  Male 47.0%
Table 1. Characteristics of the Study Population at Inclusion. (a)Antenatal visit. (b)Two drugs were used for IPTp 
according to the protocol of the MIPPAD study: sulfadoxine-pyrimethamine (SP, 1500/75 mg) and mefloquine 
(MQ: 15 mg/kg), which is given once as a full dose (MQFD) or split over 2 days (MQSD).
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During the study, 284 (71.0%) children developed at least one malaria episode (symptomatic or not): 50% of 
infected children developed two infections or more. Most of these infections were symptomatic (76.5%). There 
was no congenital infection.
At 12 months, 324 children had been followed-up and after 24 months, 189 infants had moved out of the area 
or were lost to follow-up. They were considered as censored observations. Finally all 400 infants were included in 
the survival analysis. The median duration of follow-up was 12 months.
Cox model. All the variables respected the proportional hazards assumption (Table 2).
During univariate analysis, high environmental exposure was strongly associated with an increased risk of 
first infections (p < 10−3). Neither placental malaria nor the number of peripheral maternal infections during 
pregnancy was associated with the risk of first malaria. Infants from the “not Fon” ethnic group had a lower risk 
of infection (HR = 0.7, 95%CI [0.6–0.9], p = 0.03). The level of sHLA-G (used as a quantitative variable) at ANV1 
was associated with the delay of first malaria infection (HR = 1.2, 95%CI [0.9–1.5], p = 0.05). At ANV2 and at 
delivery the association was not significant (p = 0.63 and p = 0.36 respectively). Finally, gender, environmental 
exposure, ethnic group and all variables concerning maternal HLA-G levels and malaria infections were included.
During the multivariate analysis (Table 2), both environmental exposure to malaria (aHR = 1.3, 95%CI [1.11–
1.48], p < 10−3) and s-HLAG at ANV1, used as quantitative variable, (aHR = 1.02, 95%CI [1.01–1.03], p = 0.01) 
remained significantly associated with the risk of first infection. This last result corresponds to the increase of risk 
of malaria infection when sHLA-G rises by 1 ng/mL. Using sHLA-G as a two-class variable (higher/lower that 
the median), this association was consistent with a 60% increased risk of presenting a first malaria infection for 
an infant born to a mother with high level of sHLA-G (aHR = 1.6, 95%CI [1.01–2.43, p = 0.04]) (not shown). The 
Kaplan-Meier curve (Fig. 1) shows that after 10 months of age, a high level of sHLA-G at the beginning of preg-
nancy was associated with an increased risk of a first malaria infection (Logrank test, p = 0.06).
predictive power. The introduction of the level of sHLA-G of the mother at the first ANV in the predictive 
models increased significantly the predictive power of the risk of a malaria infection during the 24 first months of 
life. Indeed, the predictive models showed that significantly higher areas under the curves (AUC) were obtained 
in presence of sHLA-G in the model performed by both logistic regression and random forest (model 2 and 
model 3) compared to a model without sHLA-G (model 1). The best predictive power has been reached when 
Covariates Unadjusted HR 95% CI p Adjusted HR 95% CI p
Gender
Male ref
Female 0.85 0.7–1.1 0.16
Low birth weight
No ref
Yes 0.8 0.5–1.3 0.33
Environmental risk(*) 1.3 1.1–1.5 <0.001 1.3 1.11–1.47 0.001
Maternal age
≤25 years ref
>25 years 1.001 0.99–1.01 0.87
Gravidity
Primigravid ref
Multigravid 0.99 0.7–1.4 0.95
Ethnic groups
Fon ref
Aïzo + others 0.7 0.6–0.9 0.03
IPT(a)
SP ref
MQFD 1.2 0.9–1.6
MQSD 0.9 0.7–1.2 0.07
Placental malaria
No ref
Yes 1.1 0.7–1.6 0.61
Peripheral infection at ANV1(b,*) 0.9 0.7–1.3 0.63
Peripheral infection at ANV2(c,*) 1.5 0.9–2.5 0.11
Peripheral infection at delivery(*) 1.13 0.8–1.5 0.43
sHLA-G at ANV1(*) 1.01 1.00–1.02 0.05 1.02 1.01–1.032 0.014
sHLA-G at ANV2(*) 1.00 0.99–1.01 0.63
sHLA-G at delivery(*) 0.99 0.99–1.00 0.35
Table 2. Risk Factors of First Malaria in the First 2 Years of Life in Infants: Univariate and Multivariate Cox 
Analysis. (*)Continuous variable. (a)Intermittent preventive treatment. (b)Antenatal visit.
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sHLA-G was considered as a binary variable (lower or higher of the median value) by the 2 methods, and the 
highest AUC was obtained by the random forest method (model 3) (Fig. 2). The AUC were 0.74, 0.84 and 0.88 
for model 1, model 2 and model 3, respectively, and Fig. 2 shows the ROC curves of the best model (model 3) 
vs. the reference model (model 1), with a significantly higher AUC of model 3 compared to the AUC of model 1 
(p = 0.01, one-sided paired test). The conclusions were similar for all the stratified partitions performed at ran-
dom, showing a good stability of the results.
Discussion
The results are consistent with an association between the mothers’ level of soluble HLA-G at the first ANV and 
the time to first malaria infection during infancy. This association persists after adjustment on environmental risk 
of exposure. Moreover, it has been shown through machine learning predictive models that the level of sHLA-G 
at the first antenatal visit is a significant predictor of the risk of malaria infection during their first 2 years of life.
In Africa, differences in transmission levels exist at the very local level. Key determinants of local transmission 
intensity include vector profile, ecology and seasonality. Therefore, localized variations ought to be taken into 
account when considering the risk of infection in a population and the determinants of individual variability (i.e. 
behavior, physiology and genetics). In the present study, substantial variations in malaria vector density have been 
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Figure 1. Kaplan-Meier survival curves in infants during the first 24 months of life according to the levels of 
sHLA-G in their mothers at the beginning of pregnancy. Plain line: low sHLA-G level (lower than the median 
value); dotted line: high sHLA-G level (higher than the median value).
Figure 2. ROC curves of the reference model (logistic regression with all covariates except sHLA-G, model 1) 
and the best model (random forest with all covariates including sHLA-G (binary), (model 3). The best model 
(model 3) AUC is significantly higher than the reference model, showing that including the sHLA-G variable in 
the model increases the predictive power of the risk of a malaria infection occurring during the 2 first years of 
the babies.
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observed at the level of both village and house, even between houses which are close together. This variability 
could be explained not only by conventional climatic factors (rainfall, season) but also certain environmental 
factors, i.e. a watercourse nearby, and vegetation index and soil type in the immediate surroundings. The environ-
mental risk of exposure has been taken into account very precisely by means of a predictive model that took into 
account both individual and environmental factors above-mentioned30. Interestingly, using this model it has been 
previously shown that the use of adequate prediction of this risk allows studying precisely the potential effect of 
placental infection in cohort studies31.The approach used in the present work is consistent with a suited manage-
ment of the environmental risk of infection in this specific context of studying the effect of placental malaria and 
of other factors on the time to first malaria infection.
Several studies have concluded in the existence of a higher susceptibility to malaria for children born to 
mothers with PM1–3. The hypothesis proposed to explain this susceptibility is the existence of an immune toler-
ance status, although there is no clear and unequivocal explanation of the mechanism involved. The cord blood 
immune response of children born to mothers with PM is characterized by inducible parasite antigen-specific 
IL-10-producing regulatory T-cells that can inhibit Th1-type T cell response32. Interestingly, the same immune 
phenomenon involving an increased level of IL-10 in cord blood has been described during pregnancy geohel-
minth infections33. Moreover, it has been shown that children born to mothers with PM are also more susceptible 
to non-malaria fever9 strengthening the hypothesis that immune tolerance could surpass a specific parasite, and 
that PM could be a biomarker of a more generalized immunosuppressive phenomenon.
Human leukocyte antigen G can inhibit a broad array of immune cells and is strongly involved in fetal maternal 
tolerance during pregnancy34. A high level of expression of HLA-G, described as an immune checkpoint molecule35, 
is also reported when cancer, viral or parasitic infections occur36,37, favoring escape from immune control. Indeed, 
HLA-G interacts with immunoglobulin-like transcript 2 (ILT2) which is expressed by T and B lymphocytes, natural 
killer (NK) cells, monocytes/macrophages and dendritic cells, and with ILT4 expressed by monocytes, macrophages, 
neutrophils and dendritic cells)38,39. Binding of HLA-G proteins to their inhibitory receptors can affect the function 
of immune cell populations modulating crucial steps in immunity40 and inducing the differentiation of CD4+ and 
CD8+ T cells into various subsets of regulatory cells that secrete IL-10 and TGF-β41,42.
The origin of sHLA-G in the mother compartment is not clearly identified. During pregnancy, the source of plas-
matic sHLA-G in mothers’ peripheral blood may come from the mother herself and/or from the fetal trophoblast 
cells. A child, a mother or both genetically committed to produce high levels of HLA-G could be more susceptible 
to infections. Therefore, the final sHLA-G production may be a combination of fetal–maternal HLA-G genotypes 
together with the micro-environmental factors that may modulate HLA-G expression43. In this context, PM may 
influence both mother and fetus HLA-G production inducing the immunological consequences listed above.
The increased malaria susceptibility of infants born of mothers with a high level of sHLA-G at the first ANV 
could be explained by several nonexclusive mechanisms. Firstly, genetic variants of the infant involved in the regu-
lation of sHLA-G expression influence the level of sHLA-G in the mother during pregnancy (via trophoblast cells) 
and in the children during infancy43. A high level of sHLA-G represents a tolerogenic environment from the infant’ 
immune system and increases the risk of infection27,28. The correlation between the level of mothers’ sHLA-G during 
pregnancy and in the infant during the first 2 years of life28 could be explained by these genetic factors. Secondly, 
high levels of sHLA-G observed at ANV1 are induced by the presence of pathogen (not necessarily malaria) escap-
ing the mothers’ immune system and also represents a tolerogenic environment from the infant’s immune system. 
Infants exposed to infection during pregnancy, combined with a strong immune system regulation on the part of 
the mother, may develop an attenuated immune response towards pathogens. This state of unresponsiveness or 
weakness of the infant’s immune system does not seem pathogen-specific but a more generalized phenomenon9.
The absence of associations between the time to the first malaria infection during infancy and the mothers’ 
levels of sHLA-G at ANV2 and delivery could be explained by the medical care provided to the mother, including 
the two doses of IPTp against malaria at each antenatal visit. They were also encouraged to attend the clinic at 
any time, whenever they had any health complaint. These different treatments received during pregnancy may 
also have modulated HLA-G expression due to the reduction of exposure to infectious diseases. However, inde-
pendently of the possible effect of IPT or of other treatment received during the follow-up, it is essential to under-
line the importance of the beginning of pregnancy per se. Indeed there is accumulating evidence that, although 
the pathophysiological mechanisms of early infections are not completely understood yet, their consequences 
are serious in terms of maternal anemia and low birth weight44. Moreover, it has been shown that even submi-
croscopic P. falciparum infections can have consequences in terms of low birth weight, prematurity and maternal 
anemia45. To our knowledge the consequences of malaria infection of the mothers during early pregnancy on the 
susceptibility of their newborns to infection during infancy have been poorly explored and the results are not 
convincing46. Our results could be indirectly consistent with the potential existence of such an association and by 
the involvement of HLA-G in this susceptibility.
It has been shown that the level of HLA-G at ANV1 has a significant predictive power of the occurrence of 
malaria infection during the first 2 years of life. This finding is promising in that it constitutes a strong argument 
for the idea that maternal HLA-G level could be a biomarker for malaria susceptibility in children. This question 
must, however, still be developed by complementary studies.
Some limitations of the study exist. Due to the constraints imposed by the clinical trial, the follow-up was 
different before and after the first 12 months. Therefore, there is a possibility that some infections could have been 
missed during the 1st year because of less extensive monitoring. Nevertheless, this possibility should in particular 
concern asymptomatic infections since mothers received the instruction to contact health centers if any health 
problems arose. However under-detection of malaria events is unlikely to be related to the maternal HLA-G level 
and this should not constitute a major and particularly specific bias in the results. Furthermore, this could explain 
why the effect of sHLA-G level seems more detectable after 10 months of life. Nevertheless, the same pattern of 
results was obtained using symptomatic infections alone (p = 0.03).
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HLA-G genetic polymorphism could influence HLA-G expression47,48 and consequently modulate the risk 
of malaria infection49. We have studied the role played by genetic polymorphism of HLA-G 3′UTR regulatory 
region. No association was observed between HLA-G 3′UTR variants and the level of sHLA-G expression (data 
not showed). However we cannot exclude that genetic variants present in HLA-G 3′UTR could modulate HLA-G 
concentration because the absence of association observed is most likely due to insufficient number of individ-
uals. Moreover, genetic variants in others regulatory regions could also affect HLA-G expression50,51. Studies 
combining in vitro functional assays and larger cohorts are needed to better understand the role played by genetic 
on HLA-G expression.
The potential advantage of soluble HLA-G as a biomarker has already been proposed in cancer, chronic viral 
infections and in vitro fertilization20–22. Our results are consistent with the potential value of sHLA-G from a 
public health point of view to identify pregnancies that could result in particularly frail newborns. However, we 
believe it is too early to make some recommendation for the follow-up of women and newborn, and we need to 
confirm these results in another population including a higher number of pregnant women.
Material and Methods
study site and population. The present prospective cohort study took part in the framework of the 
MiPPAD clinical trial (http://clinicaltrials.gov/ct2/show/NCT00811421). The first 400 infants to be delivered 
were enrolled from January 2010 to June 2011, and followed up for 24 months. HIV-positive, twin pregnancies, 
stillbirth or fetal abnormalities were excluded. Women were included before the end of 28 gestational weeks 
(GW) and two doses of Intermittent Preventive Treatment for pregnancy (IPTp) were administered at antenatal 
visits (ANVs)52. In our analyses ANV1 and ANV2 referred respectively to the ANVs during which the first and 
the second IPTp doses were given, in compliance with the MiPPAD clinical trial protocol.
study procedures. At inclusion, socio-demographic and socio-economic characteristics, reproductive and 
medical histories were collected. Women were examined and a questionnaire completed. Between ANVs, women 
had to attend the health centre for all health complaints.
Blood was sampled (before IPTp administrations at ANV1 and ANV2 and before delivery) for plasma 
sHLA-G measurement and malaria diagnosis. After delivery, a placental blood smear was used to assess placental 
malaria, defined as the presence of asexual Plasmodium falciparum parasites in the blood smear.
Newborns were followed until 24 months. Due to the MiPPAD clinical trial constraints, the follow-up was dif-
ferent before and after 12 months. During the first year of life, at 6, 9 and 12 months children were clinically exam-
ined. In case of axillary temperature greater than or equal to 37.5 °C (or a history of fever in the preceding 24 h) a 
rapid diagnosis test (RDT) and a thick blood smear (TBS) were performed. After 12 months of age, children were 
visited at home twice a month and the temperature was systematically checked. During the 24-month period, 
mothers were invited to visit health centers if there was any health problem. During home visits or at the health 
center, in case of fever or history of fever in the preceding 24 h, a RDT was performed. Monthly between 12 and 
24 months, a systematic TBS to detect asymptomatic malaria was also performed. A symptomatic malaria attack 
was defined as the presence of fever (or a history of fever) and a positive RDT and/or a positive TBS. Malaria 
attacks were treated with an artemisinin-based combination (arthemeter and lumefantrine), as recommended by 
the Beninese National Malaria Control Program. An asymptomatic infection was defined as a positive monthly 
systematic TBS with no fever or history of fever. Overall, at birth (cord blood), 6, 9, 12, 18 and 24 months, blood 
was collected to perform the same tests evaluated in mothers. All the medications prescribed were free of charge.
Soluble HLA-G quantification. Soluble HLA-G was quantified using the MEM-G/9 antibody (Exbio, 
Praha, Czech Republic), which recognizes the sHLA-G1, -G5 isoforms and the anti-human β2-microglobulin, 
as capture and detection antibodies, respectively53. All incubation steps were performed at room temperature, 
followed by four washes using washing buffer (H2O, PBS 1X, 0.1% Tween 20). The plates were incubated for 
30 min with the substrate (Tetramethylbenzidine, Sigma Aldrich, St. Louis, MO, USA) and absorbance was meas-
ured at 450 nm after adding HCL (1 N). Total sHLA-G levels were determined from a five-point standard curve 
(12.5–200 ng/mL) using dilutions of calibrated HLA-G5 purified from M8-HLA-G5 cell line culture supernatant, 
and the results were expressed as ng/mL. The detection limit is ~1 ng/mL. A negative and positive control was 
included in each ELISA plate. The positive control was the supernatant from M8-HLA-G5 cell line culture (with 
the vector encoding the secreted protein HLA-G5 (M8-HLA-G5)) while the negative control was the supernatant 
from M8 cell line transfected with the empty vector (M8-pcDNA).). Both M8-HLA-G5 and M8-pcDNA cell lines 
were previously described54. The precise concentration of HLA-G5 present into the M8-HLA-G5 supernatant 
was defined using HLA-G5 purified protein55. The methodology to measure sHLA-G1 and -G5 molecules using 
ELISA has been previously validated the Wet Workshop for measurement of sHLA-G held in Essen, Germany 
and published56.
Definition of variables. For survival analysis, time between birth and first malaria infection (symptomatic 
or not) was defined as primary outcome. After their first malaria infection, children were right-censored. The date 
of right censoring was the date of first malaria infection or the last available date of follow-up.
The following variables were used. Gender of the newborn; presence of LBW (birth weight <2500 g); age of 
the mother; gravidity (primi vs multigravid); ethnic group (Aizo, Fon, other); IPTp treatment group; placental 
malaria infection (presence/absence); number of peripheral malaria infections during pregnancy (before ANV1, 
between ANV1 and ANV2 and after ANV2); level of sHLA-G at ANV1, at ANV2 and at delivery. Levels of 
sHLA-G at each measurement were used as quantitative variable. The environmental risk of infection was assessed 
through quantification of exposure to vector bites. Mosquito catches were performed over two consecutive nights, 
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monthly throughout the course of the study, to assess the density of malaria vectors. Using environmental (rain-
fall, type of soil, watercourse nearby, vegetation index) and behavioral data (number of inhabitants per room; 
ownership of a bed net or insect repellent), a time- and space-dependent environmental risk of exposure to 
malaria was assessed for each child by means of a predictive model30.
statistical analyses. Survival analyses. A Cox regression model was used to assess the effect of PM and 
of the mothers’ sHLA-G levels on the time of first infection, adjusted on the cofactors mentioned above. First, a 
univariate Cox analysis was performed to study the association between all covariates and the first malaria infec-
tion. Kaplan-Meier curves were obtained to present the probability of occurrence of malaria infection. Secondly, 
a multivariate analysis was performed to study the association between first malaria infection and PM or mothers’ 
HLA-G levels, adjusting for the covariates selected in the first step (with p < 0.20). Scaled Schoenfeld residuals 
were used for testing the proportional-hazards assumption.
Data were analyzed using the Stata v. 13 software (Stata Corporation, College Station, TX, USA).
Predictive analyses. Complementary, we built a predictive model, designed to evaluate the power of sHLA-G 
to predict the occurrence of infection during the 2 years follow-up (no infection vs at least one). We performed 
two machine-learning methods: logistic regression and random forest. For both methods, the same steps were 
followed. First, the sample was split into a train sample (70% of the data) and a test sample (30% of the data) 
randomly drawn with stratification according to the malaria infection status to guarantee the same proportion 
of infection in both samples. At a second step different predictive models were built (see details below) using the 
train sample and at the last step, the predictive power of each model was evaluated using the test sample through 
the area under ROC curves (AUC). All the covariates were introduced in the predictive models, which differed 
only according to the way the sHLA-G variable has been considered: (i) sHLA-G as a binary variable (2 classes 
according to the median, (ii) sHLA-G as a four classes variable (according to the quartiles) and (iii) sHLA-G as 
a continuous variable. Then, the best sHLA-G variable was selected (i.e. the sHLA-G variable giving the high-
est predictive power (highest AUC) was selected. At last, three models were compared by testing the difference 
between the areas under the ROC curves: logistic regression with all covariates except sHLA-G (model 1 consid-
ered as the reference model), logistic regression with all covariates including the best sHLA-G variable (model 2) 
and random forest with all covariates including the best sHLA-G variable (model 3). Finally, the stability of the 
results has been checked by repeating this last step on 4 other partitions of the data drawn at random (i.e. 5 pairs 
of train/test samples in all). These analyses were performed using R software, (MLR package).
ethics. The study protocol and informed consent were approved by the Comité Consultatif de Déontologie et 
d'Éthique (CCDE) of the Institut de Recherche pour le Développement (France) and by the Ethics Committee of the 
Faculté des Sciences de la Santé de Cotonou in Benin (N° 43/11/2010/CE/FSS/UAC). Written informed consent 
was signed and a copy was given to each participant with the possibility to withdraw at any time. If the woman 
could not read, an impartial witness was involved in the process. In addition to the assent of minors, informed 
consent was obtained from the parents or legal guardians. All the methods were carried out in accordance with 
the approved guidelines.
Data Availability
All relevant data are available from the Open Science Framework database (https://osf.io/q2v57/).
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